Methylphenidate in a Patient with Depression and Respiratory Insufficiency

Ayache, Danusa Céspedes Guizzo; Fráguas, Renério

doi:10.2190/cxne-0ufr-7q04-cq3m

Cited by 4 publications

(3 citation statements)

References 9 publications

(9 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A prospective trial of methylphenidate for negative symptoms such as anhedonia and psychomotor retardation in patients with Alzheimer's disease or vascular dementia64 reported significant improvement in symptoms scores, but did not provide response rates. Reports of successful uses of methylphenidate in the literature include treatment of lethargy and depressive symptoms in mechanically ventilated patients who are difficult to wean,75, 76 treatment of anorexia in apathetic, severely demented nursing home residents,77, and treatment of depressive symptoms in patients up to 106 years of age 78…”

Section: Resultsmentioning

confidence: 99%

Methylphenidate for the treatment of depressive symptoms, including fatigue and apathy, in medically ill older adults and terminally ill adults

Hardy

2009

The American Journal of Geriatric Pharmacotherapy

102

View full text Add to dashboard Cite

show abstract

Section: Resultsmentioning

confidence: 99%

Methylphenidate for the treatment of depressive symptoms, including fatigue and apathy, in medically ill older adults and terminally ill adults

Hardy

2009

The American Journal of Geriatric Pharmacotherapy

102

View full text Add to dashboard Cite

show abstract

“…The most frequent use was the combination of methylphenidate with citalopram in four trials for depression, showing significant improvement of the patients’ symptoms, as assessed by the Hamilton Depression Rating Scale [ 28 ], and good tolerability [ 29 - 32 ]. Other eleven trials were conducted for different conditions: post-stroke depression [ 33 , 34 ], Parkinson’s disease [ 35 , 36 ], falls [ 13 ] age-related cognitive decline [ 36 ], post-stroke rehabilitation [ 38 , 39 ], and medically-ill patients with depressive symptoms [ 40 - 42 ].…”

Section: Resultsmentioning

confidence: 99%

Amphetamine Use in the Elderly: A Systematic Review of the Literature

Sassi

Rocha

Colpo

et al. 2020

View full text Add to dashboard Cite

Objective: To systematically review the literature on the therapeutic use of amphetamine, lisdexamfetamine and methylphenidate in elderly population with and without dementia. Methods: We conducted two researches on the PubMed, Scopus and Embase using the keywords (“elderly”) AND (“amphetamine” OR “methylphenidate” OR “lisdexamfetamine”) and then (“Alzheimer” OR “dementia”) AND (“amphetamine” OR “methylphenidate” OR “lisdexamfetamine”). Results: Twenty-nine papers met all the eligibility criteria. The results are encouraging as 81.5% of the studies showed clinical improvement of the investigated condition. Conclusion: Amphetamines and methylphenidate are probably effective strategies for different conditions in the elderly population. However, further studies are needed to provide more robust evidence on efficacy, dosage and safety for this population.

show abstract

“…Psychostimulants appear to be reasonably safe even in those with respiratory insufficiency. 25 Although most experience improvement in target symptoms, some will experience worsening symptoms compatible with S/E so it is important to monitor symptom profiles in those on MP. Multiple studies have shown a low risk for MP abuse though caution should be used in those with a history of addiction.…”

Section: Discussionmentioning

confidence: 99%

Methylphenidate Side Effects in Advanced Cancer: A Retrospective Analysis

Lasheen

Walsh

Mahmoud

et al. 2009

Am J Hosp Palliat Care

View full text Add to dashboard Cite

Introduction Methylphenidate (MP) is often recommended for symptom control in advanced cancer. Little is known about its side effects in frail adults. Objectives To evaluate MP associated symptoms or side effects (S/E) in three symptom studies among patients with advanced cancer. Methods Data was collected from two published prospective cohort series and a phase 2 study of MP for symptom control in advanced cancer. All three reports had identical dosing schedules and symptom assessments. Initial MP doses were 10 mg/d (5 mg at 8 a.m. and at 12 noon) titrated up to a maximum of 30 mg/d. Depression, fatigue, and symptoms identified as possible MP S/E (agitation, anorexia, dizziness, dry mouth, headache, insomnia, nausea, palpitation, tremors, vomiting) were evaluated for presence (prevalence) and for severity (using categorical scales) before MP (day 0) and on days 3, 5 and 7 thereafter. The categorical scale used was none, mild, moderate, and severe. For this analysis all who received at least one dose of MP were evaluable for potential S/E, and those who completed 7 consecutive days therapy were evaluable for efficacy. Results 62 patients were enrolled. 50 completed 7 days of MP with a median age of 69 (range 30-90) years. Thirty-five received MP 10 mg/day, one 15 mg/day, thirteen 20 mg/day, and one 30 mg/d of MP by day 7. Most (96 %) had improvement in depression and/or fatigue. Amongst the 62 patients new symptom prevalence throughout the study was; agitation (16%), insomnia (16%), dry mouth (15%), nausea (10%), tremors (6%), anorexia (5%), headache (3%), palpitations (2%), and vomiting (2%). Patients could have more than one symptom simultaneously. Seven patients (11%) withdrew due to MP S/E. Moderate symptoms occurred in 10 people during the study period, but none had severe symptoms. Some symptoms present before MP showed significant improvement during MP therapy; agitation [0.48±0.68 to 0.32±0.55 (P<0.029)], anorexia [0.86±1.00 to 0.67±0.83 (P<0.008)], and dizziness [0.14±0.40 to 0.06±0.31 (P<0.011)]. Conclusions 1) Treatment with MP (10-20 mg/d) in advanced cancer is well tolerated; only 11% withdrew due to MP S/E. 2) S/E symptoms occurring with MP appeared to improve spontaneously despite continued MP therapy. The commonest new symptoms after MP started were agitation (16%), insomnia (16%), and dry mouth (15%). 3) Depression and fatigue improved at doses lower than those recommended in other clinical conditions. 4) MP improved depression and fatigue, and some secondary symptoms associated with them. Methylphenidate (MP) appears safe when used in the treatment of depression and fatigue in advanced cancer.

show abstract

Methylphenidate in a Patient with Depression and Respiratory Insufficiency

Abstract: Methylphenidate may be useful for patients with severe medical conditions including ventilatory insufficiency.

Cited by 4 publications

References 9 publications

Methylphenidate for the treatment of depressive symptoms, including fatigue and apathy, in medically ill older adults and terminally ill adults

Methylphenidate for the treatment of depressive symptoms, including fatigue and apathy, in medically ill older adults and terminally ill adults

Amphetamine Use in the Elderly: A Systematic Review of the Literature

Methylphenidate Side Effects in Advanced Cancer: A Retrospective Analysis

Contact Info

Product

Resources

About